LifeArc partners with Elpida Therapeutics to advance three gene therapies for ultra-rare neurodegenerative diseases in childrenLifeArc provides tailored clinical, translational and regulatory expertise, alongside financial support to accelerate development of programmes targeting SPG50, CLN7 Batten disease and CMT4JThe first patients...